Spots Global Cancer Trial Database for Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Official Title: An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma
Study ID: NCT05079282
Conditions
Interventions
Study Description
Brief Summary: This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States
Oregon Health & Science University, Portland, Oregon, United States
UT Southwestern Medical Center, Dallas, Texas, United States
MD Anderson, Houston, Texas, United States
Contact Details
Name: Project Leader
Affiliation: Ono Pharma USA Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
